OSIR (Osiris Therapeuti)
All Pro Portfolios with OSIR

People owning OSIR also tend to own:: CHKCHTRIDTIGOMRIPFEPPHM

All Do-It-Yourself Portfolios with OSIR
  • News For Selected Stock
  • Related stories on theStreet.com
  • videos related to etf's
  • No videos found
  •  
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:sfmain

Date:08 31 09

options value

Not yet rated
Rate now:

By:Trading Nymph

Date:01 10 09

9

Not yet rated
Rate now:

By:Dan Jacobs

Date:01 14 08

stem cell / defense /biotech play featured in Investors Business Daily. The company uses adult stem cells to repair GI tract after radiation exposure.

Not yet rated
Rate now:

By:Dan Jacobs

Date:01 14 08

stem cell / defense /biotech play featured in Investors Business Daily. The company uses adult stem cells to repair GI tract after radiation exposure.

Not yet rated
Rate now:

By:gman0412

Date:12 07 07

i think it a good stock,its at the low and got fast

Not yet rated
Rate now:

By:rentman

Date:08 23 07

news

Not yet rated
Rate now:

By:Jamie Fitch

Date:05 17 07

Osiris Therapeutics is focusing on using mesenchymal stem cells (MSCs). these cells come from adult bone marrow. They are interesting in that they are not highly specialized and can be converted into a variety of connective tissues using specific enzymes (they are the adult stell cells most similar to embyronic stem cells). Osiris is currently looking to use MSCs to treat inflammatory diseases, heart disease, and to aid in spinal fusions. They already have one product in the market (Osteocel) for spinal fusions. This product helps create the spongy interior of bones and aids in fusion. It is the only stem cell treatment that is on the market (as of Dec 06). Additionally, they have three other products in phase I-III stage clinical trials. This bodes well for the company. While their financials have been ugly of late, at least this company has a treatment on the market. Additionally, research approaching advanced trials on diseases such as Crohn's disease could pay off in the somewhat near future. Finally, it has been able to harbor MSCs to create a wide variety of tissues, much like embryonic cells will be able to do. This makes me believe they will be able to adapt and use the new + presumably more potent cells quickly. They have shown the ability to get a stem cell product to the market, which is extremely challenging. Unlike STEM, this company will rely more on its products and less on its potential to convince investors to back them. They are probably the furthest along of all of companies I will be considering in stem cell therapy techniques.

Not yet rated
Rate now:

By:Barrons

Date:05 05 07

"Provacel stem-cell treatment for heart disease."

Not yet rated
Rate now:

By:mldillon

Date:04 18 07

BSR pick, mesenchymal cell technology, clinical therapeutic trials

Not yet rated
Rate now:

By:Calculatorci

Date:04 09 07

Stem Cell,Cardiac Play

Not yet rated
Rate now:

Why I Hate This Stock

By:rnaia

Date:09 05 09

LOSS

Not yet rated
Rate now:
Add Your Comments  
Stock OSIR
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Cramer's Take on Headline Stocks...

Posted on Dec. 3, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...

12.03.09 | 14:40 PM
'Fast Money' Portfolios of the Week

By Roberto Pedone Posted on Dec. 3, 2009 The traders of CNBC’s “Fast Money” think the path of least resistance for the stock market remains to the upside. On Tues...

12.03.09 | 12:05 PM
Cramer's Take on Headline Stocks...

Posted on Dec. 2, 2009 Not a Stockpickr member? Join the community today -- for free. Regardless of why a stock is in the news, it never hurts to hear what a professi...

12.02.09 | 16:46 PM
Short Squeezing the Regional Banks

By Jonas Elmerraji Posted on Dec. 2, 2009 It’s been a tough year for regional banks. While investors mulled over the fate of the big three banks -- Citigroup (C), Ban...

12.02.09 | 12:51 PM
more articles
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
Other People's Ideas (OPI)
11.28.09 | 15:23 PM From author Valerie J
more forums
today 's lists
Analyst Upgrades

Analyst Upgrades for Dec. 3, 2009. Read more here. more

Rising on Unusual Volume

Here are some stocks that moved up on unusual volume on Dec. 2, 2009. more

Earnings Announcements

Here is a list of some of the companies that will report earnings on Friday (Dec. 4, 2009). For some of the companies below, EPS estimates* are provided. * Analyst op... more